Document is current
Any future updates will be listed below
-
Authors
Nathoo, Nabeela https://orcid.org/0000-0001-6446-1146
Uhm, Joon H.
Porter, Alyx B.
Hammack, Julie
Jaeckle, Kurt A.
Mrugala, Maciej M.
Crum, Brian A.
Flanagan, Eoin P.
Pittock, Sean J.
Goyal, Gaurav
Young, Jason R. https://orcid.org/0000-0001-5351-8266
Koster, Matthew J.
Vassallo, Robert https://orcid.org/0000-0003-2328-0255
Ryu, Jay H. https://orcid.org/0000-0002-9576-2272
Davidge-Pitts, Caroline J.
Bach, Corrie
Ravindran, Aishwarya
Sartori Valinotti, Julio C.
Bennani, N. Nora https://orcid.org/0000-0001-8358-5953
Abeykoon, Jithma P. https://orcid.org/0000-0003-3939-6252
Shah, Mithun V. https://orcid.org/0000-0002-5359-336X
Hook, C. Christopher
Rech, Karen L. https://orcid.org/0000-0001-6770-2339
Go, Ronald S. https://orcid.org/0000-0002-8284-3495
Tobin, W. Oliver https://orcid.org/0000-0002-8141-2394
,
Gruber, Lucinda M.
- License Information
-
More Information
Article History
Received: 21 April 2024
Revised: 5 June 2024
Accepted: 11 June 2024
First Online: 20 June 2024
Competing interests
: N. Nathoo, J. Uhm, A. Porter, J. Hammack, K. Jaeckle, M. Mrugala, B. Crum, J. Abeykoon, C.C. Hook, J.R. Young, J.H. Ryu, C.J. Davidge-Pitts, A. Ravindran, K.L. Rech, and R.S. Go declare that they have no financial interests. E.P. Flanagan has served on Alexion, Genentech, Horizon Therapeutics, and UCB advisory boards. He has received research support from UCB. He has received speaker honoraria from Pharmacy Times. He received royalties from UpToDate. Dr Flanagan was a site primary investigator in a randomized clinical trial on Inebilizumab in neuromyelitis optica spectrum disorder run by Medimmune/Viela-Bio/Horizon Therapeutics. Dr Flanagan has received funding from the NIH (R01NS113828). Dr Flanagan is a member of the medical advisory board of the MOG project. Dr Flanagan is an editorial board member of the Journal of the Neurological Sciences and Neuroimmunology Reports. A patent has been submitted on DACH1-IgG as a biomarker of paraneoplastic autoimmunity. S.J. Pittock reports grants, personal fees, and non-financial support from Alexion Pharmaceuticals; grants, personal fees, and non-financial support from MedImmune /Viela Bio; and personal fees for consulting from Genentech, Roche, UCB, and Astellas. He has two patents issued (8889102; application 12-678350; Neuromyelitis Optica Autoantibodies as a Marker for Neoplasia; and 9891219B2; application 12-573942; Methods for Treating Neuromyelitis Optica [NMO] by Administration of Eculizumab to an individual that is Aquaporin-4 [AQP4]-IgG Autoantibody positive). Sean J. Pittock also has patents pending for IgGs to the following proteins as biomarkers of autoimmune neurological disorders: septin-5, kelch-like protein 11, GFAP, PDE10A, and MAP1B. J.C. Sartori Valinotti had received consulting fees from Novartis Pharmaceuticals Corporation. G. Goyal is on the advisory board of Opna Bio LLC and has received royalties from UpToDate; he has also received research funding from Seagen, Sutro Biopharma, and Viracta Therapeutics. M.J. Koster has received institutional grant funding from Genentech. R. Vassallo has received research grants from Pfizer, Bristol Myers Squibb, and Sun Pharma. N.N. Bennani serves as an unpaid Advisory Board member of Daichii Sankyo, Inc.; Kyowa Kirin; Vividion Therapeutics, Kymera, Secura Bio; Affimed, GmbH; Astellas Pharma, and Acrotech Biopharma, LLC. M.V. Shah receives research support from AbbVie, MRKR Therapeutics, Celgene, and Astellas. W.O. Tobin has received grants from the National Institutes of Health, Mallinckrodt Inc., speaking fees from NeurologyLive, DKBMed, and book royalties from the publication of Mayo Clinic Cases in Neuroimmunology (Mayo Clinic Scientific Press) 2022.
: This study was approved by the Institutional Review Board of Mayo Clinic, Rochester, Minnesota (Institutional Review Board 17-004541). This study adhered to the Declaration of Helsinki.
: All patients provided written consent for the use of their de-identified medical information for research and publication.
